>Европейский рынок лечения заболеваний опорно-двигательного аппарата (MSK), по типу (цифровая система биологической обратной связи, цифровые приложения, решения, ориентированные на опорно-двигательный аппарат, и другие), технологиям (технология точного движения, технология компьютерного зрения и другие), типу интеграции (телефон, планшет, компьютер и другие), модальности (виртуальная терапия, очная терапия, индивидуальная/персонализированная терапия и другие), применению (предоперационные и послеоперационные приложения), популяции пациентов (педиатрия, взрослые и гериатрия), конечный пользователь (больницы и клиники, дома престарелых , медицинские центры, реабилитационные центры, виртуальные/домашние медицинские учреждения и другие) — отраслевые тенденции и прогноз до 2030 года.
Анализ и аналитика европейского рынка лечения заболеваний опорно-двигательного аппарата (MSK)
Растущий спрос на технологические достижения в диагностике заболеваний опорно-двигательного аппарата, повышение осведомленности о заболеваниях опорно-двигательного аппарата, растущая распространенность ревматоидного артрита (РА) и увеличение случаев переломов костей являются факторами, которые, как ожидается, будут способствовать росту рынка.
С другой стороны, стратегические инициативы участников рынка, разработка продуктов, использование телемедицины в лечении заболеваний опорно-двигательного аппарата, а также более широкое использование мобильных аппаратов и домашнего ухода для лечения заболеваний опорно-двигательного аппарата могут стать возможностью для роста рынка.
Однако ожидается, что высокая стоимость диагностики и лечения ортопедических заболеваний, а также рост использования сильнодействующих препаратов для лечения болей в опорно-двигательном аппарате будут сдерживать рост рынка.
Ожидается, что растущий спрос на использование управления заболеваниями опорно-двигательного аппарата при разработке и проектировании лекарств будет способствовать росту рынка в Европе. Data Bridge Market Research анализирует, что рынок управления заболеваниями опорно-двигательного аппарата (MSK) в Европе будет расти со среднегодовым темпом роста 22,2% в течение прогнозируемого периода с 2023 по 2030 год.
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2023-2030 |
|
Базовый год |
2022 |
|
Исторический год |
2021 (Можно настроить на 2023–2030 гг.) |
|
Количественные единицы |
Доход в млн. долл. США, цены в долл. США |
|
Охваченные сегменты |
По типу (цифровая система биологической обратной связи, цифровые приложения, решения, ориентированные на опорно-двигательный аппарат, и другие), технологии (технология точного движения, технология компьютерного зрения и другие), типу интеграции (телефон, планшет, компьютер и другие), модальности (виртуальная терапия, очная терапия, индивидуальная/персонализированная терапия и другие), применению (предоперационные и послеоперационные приложения), популяции пациентов (педиатрия, взрослые и гериатрия), конечный пользователь (больницы и клиники, дома престарелых, медицинские центры, реабилитационные центры, виртуальные/домашние медицинские учреждения и другие) |
|
Страны, охваченные |
Германия, Франция, Великобритания, Италия, Испания, Россия, Турция, Бельгия, Нидерланды, Дания, Швейцария, Швеция, Польша, Норвегия, Финляндия и остальная Европа |
|
Охваченные участники рынка |
RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH и Limber Health, Inc. и другие |
Определение рынка
Заболевания или нарушения опорно-двигательного аппарата (MSK) включают в себя более 150 различных заболеваний или состояний, которые внутренне влияют на человеческую систему и характеризуются недостатками в мышцах, костях, суставах и прилегающих соединительных тканях, что приводит к пожизненным препятствиям в функционировании и участии. Эти состояния характеризуются болью, ограниченным движением походки и ловкостью, тем самым снижая способность людей работать и участвовать в жизни общества.
Лечение заболеваний опорно-двигательного аппарата подразумевает консультацию врача, интегрированную с телемедициной, которая представляет собой использование систем цифровой биологической обратной связи (DBS), MDA и терапий. Физическая активность и программы контроля веса также являются важными видами деятельности по самоконтролю для людей с артритом. Виртуальная терапия или удаленная консультация подразумевает целостный подход с внедрением видеоконференций и телефонных консультаций в практику MSK.
- В ближайшем будущем важные решения, связанные с лечением заболеваний опорно-двигательного аппарата, физическими движениями и послеоперационными применениями, будут приниматься людьми, которые не только разбираются в телемедицине и виртуальных технологиях, но и могут использовать инструменты лечения заболеваний опорно-двигательного аппарата и полученные с их помощью знания для разработки гипотез и определения качественных целевых показателей.
Динамика рынка лечения заболеваний опорно-двигательного аппарата в Европе
Драйверы
- Технологические достижения в диагностике заболеваний опорно-двигательного аппарата (ЗОД)
Заболевания опорно-двигательного аппарата (ОСМ) — это травмы и расстройства, которые влияют на движение человеческого тела в системе ОСМ, например, мышц, связок, нервов, сухожилий, хрящей и дисков. Некоторые из распространенных заболеваний ОСМ — это миастения, остеоартрит (ОА), подагра, РА, боли в спине, остеопороз и системная красная волчанка (СКВ). Боль в ОСМ может иметь различные причины, например, мышечная ткань может быть повреждена из-за износа во время повседневной деятельности. Нагрузка на части тела человека из-за растяжений, автомобильных аварий, падений, резких движений, переломов, вывихов и прямых ударов мышц также вызывает боль в ОСМ.
- Рост числа случаев переломов костей
Перелом — это медицинское определение сломанной кости. Переломы обычно являются результатом травм, таких как падения, автомобильные аварии или спортивные травмы. Однако определенные медицинские состояния и повторяющиеся силы (например, бег) могут увеличить риск определенных типов переломов. Если на кость оказывается большее давление, чем она может выдержать, она треснет или сломается. Перелом любого размера называется переломом. Если перелом прокалывает кожу, он называется открытым переломом (сложный перелом). Стрессовый перелом — это перелом, возникающий в результате повторяющихся или продолжительных сил, действующих на кость. Повторяющееся напряжение ослабляет кость, пока она в конечном итоге не сломается.
Возможности
- Использование телемедицины в лечении заболеваний опорно-двигательного аппарата (ОДА)
Телемедицина предоставляет пациентам экономически эффективную и качественную помощь. Планирование предварительного визита позволяет осуществлять надлежащее внедрение телемедицины, что гарантирует предоставление пациентам и врачам функционального телемедицинского оборудования. Врачи, занимающиеся лечением заболеваний опорно-двигательного аппарата, выполняют структурированное обследование опорно-двигательного аппарата с помощью телемедицины. Использование обычных предметов домашнего обихода позволяет врачам воспроизводить клинические осмотры в очном режиме. Инструкции по уходу на дому и онлайн-реабилитация обеспечивают начальное управление лечением.
- Стратегические инициативы ключевых игроков рынка
Рост заболеваний опорно-двигательного аппарата (MSK) увеличивает потребность в стратегических бизнес-идеях. Это включает партнерство, расширение бизнеса, сотрудничество и другие разработки. На европейском рынке управления заболеваниями опорно-двигательного аппарата (MSK) многие агентства здравоохранения и участники рынка влекут за собой инициативы, которые призваны обеспечить возврат инвестиций для клиентов. Запланированные стратегии позволяют участникам рынка согласовываться с функциональной деятельностью организации для достижения поставленных целей. Это направляет обсуждения и принятие решений компании при определении потребностей в ресурсах и бюджете для достижения целей, тем самым повышая операционную эффективность.
Ограничения/Проблемы
- Высокая стоимость диагностики и лечения ортопедических заболеваний
Хронические ортопедические заболевания, такие как артрит и бурсит, поражают систему опорно-двигательного аппарата — чаще всего кости или суставы. Они могут вызывать боль и дисфункцию, затрудняя повседневную деятельность. Эти состояния отличаются от ортопедических травм, таких как вывих плеча или перелом кости, которые часто возникают в результате внезапной травмы. В отличие от случайных или травматических ортопедических травм, хронические заболевания обычно прогрессируют, начинаются медленно и ухудшаются или развиваются с течением времени. Они могут быть генетическими или возрастными, или они могут быть вызваны чрезмерной нагрузкой.
Некоторые ортопедические состояния поддаются лечению, а некоторые не могут быть вылечены в настоящее время, но могут быть вылечены для уменьшения боли и улучшения качества жизни. Точная диагностика и целенаправленное лечение могут помочь уменьшить проблемы даже в прогрессирующих состояниях без лечения. Рекомендации по лечению зависят от типа и тяжести вашего состояния. Лечение варьируется от RICE (покой, лед, компрессия и подъем) до серьезной хирургии.
- Рост использования сильнодействующих препаратов для лечения боли в опорно-двигательном аппарате
Боль в опорно-двигательном аппарате — это сложное состояние для пациентов и врачей. Многие взрослые, независимо от возраста, пола или экономического положения, испытывали один или несколько эпизодов боли в опорно-двигательном аппарате в какой-то момент своей жизни. Она затрагивает около 47% населения. Около 39–45% из них представляют собой долгосрочные проблемы, требующие консультации врача. Неправильно леченная боль в опорно-двигательном аппарате может снизить качество жизни и вызвать серьезные социально-экономические проблемы.
Мультимодальная анальгезия и междисциплинарные подходы являются ключевыми элементами эффективного лечения боли в опорно-двигательном аппарате. Как фармакологическое, так и нефармакологическое и интервенционное управление болью важны для улучшения восстановления, благополучия и качества жизни пациента. Таким образом, недавние рекомендации рекомендуют профилактические стратегии и физические инструменты для снижения потребления наркотиков. У пациентов, которые не отреагировали адекватно на лечение, надлежащее использование интервенционного управления болью и других альтернативных методов имеет решающее значение для безопасного и эффективного лечения пациентов с хронической болью.
Влияние COVID-19 на европейский рынок лечения заболеваний опорно-двигательного аппарата (MSK)
Во время пандемии симптомы лечения заболеваний опорно-двигательного аппарата сохраняются после выздоровления от COVID-19, наиболее распространенными жалобами являются усталость, боль в спине, артралгия, миалгия, боль в пояснице и боль в шее. Лечение заболеваний опорно-двигательного аппарата увеличивает использование виртуальной терапии, телемедицины и цифровой реабилитационной службы.
В условиях пандемии COVID-19 телемедицина может использоваться поставщиками медицинских услуг для предоставления услуг по реабилитации пациентам с различными заболеваниями опорно-двигательного аппарата. Текущие данные свидетельствуют о том, что для некоторых заболеваний опорно-двигательного аппарата телемедицинская оценка может быть надежной, лечение может быть эффективным, а удовлетворенность пациентов может быть хорошей или лучше, чем при стационарном лечении.
Последние события
- В апреле 2022 года Airrosti Rehab Center, LLC заключил партнерство с инновационным рынком здравоохранения Buoy Health. Результатом партнерства стало предоставление высококачественной медицинской помощи MSK более чем 2 миллионам пользователей Buoy в месяц и разработка новых виртуальных продуктов MSK.
- В марте 2022 года компания DarioHealth Corp. заключила договорное соглашение с Sanofi US. Соглашение было направлено на ускорение коммерческого роста компании DarioHealth Corp. в области цифрового портфеля решений по управлению заболеваниями опорно-двигательного аппарата и разработку цифровых медицинских решений на платформе DarioHealth Corp.
Европейский рынок лечения заболеваний опорно-двигательного аппарата (MSK)
Европейский рынок лечения заболеваний опорно-двигательного аппарата (MSK) сегментирован на семь заметных сегментов на основе типа, технологии, типа интеграции, модальности, применения, популяции пациентов и конечного пользователя. Рост среди этих сегментов поможет вам проанализировать сегменты с незначительным ростом в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи, которые помогут им принимать стратегические решения для определения основных рыночных приложений.
Тип
- Цифровая система биологической обратной связи
- Цифровые приложения, ориентированные на опорно-двигательный аппарат (MDAS)
- Решения
- Другие
По типу рынок сегментируется на цифровые системы биологической обратной связи, цифровые приложения для опорно-двигательного аппарата (MDA), решения и другие.
Технологии
- Технология точного движения
- Технология компьютерного зрения
- Другие технологии
В зависимости от технологии рынок сегментируется на технологии точного движения, технологии компьютерного зрения и другие технологии.
Тип интеграции
- Телефон
- Планшет
- Компьютер
- Другие
По типу интеграции рынок сегментируется на телефоны, планшеты, компьютеры и т. д.
Модальность
- Виртуальная Терапия
- Личная терапия
- Индивидуальная/персонализированная терапия
- Другие
По модальности рынок сегментируется на виртуальную терапию, личную терапию, индивидуальную/персонализированную терапию и другие.
Приложение
- Предоперационные приложения
- Применение после операции
По сфере применения рынок сегментирован на предоперационное и послеоперационное применение.
Пациенты
- Педиатрия
- Взрослые
- Гериатрия
В зависимости от численности пациентов рынок сегментирован на педиатрию, взрослых и гериатрию.
Конечный пользователь
- Больницы и клиники
- Дома престарелых
- Центры здоровья
- Реабилитационные центры
- Виртуальные/домашние настройки медицинского обслуживания
- Другие
В зависимости от конечного пользователя рынок сегментируется на больницы и клиники, дома престарелых, медицинские центры, реабилитационные центры, виртуальные/домашние медицинские учреждения и другие.
Региональный анализ/информация о рынке лечения заболеваний опорно-двигательного аппарата в Европе
Проведен анализ европейского рынка лечения заболеваний опорно-двигательного аппарата (MSK), а также предоставлены сведения о размерах рынка и тенденциях по регионам, типам, технологиям, типам интеграции, модальностям, областям применения, группам пациентов и конечным пользователям, как указано выше.
Страны, охваченные этим рыночным отчетом: Германия, Франция, Великобритания, Италия, Испания, Россия, Турция, Бельгия, Нидерланды, Дания, Швейцария, Швеция, Польша, Норвегия, Финляндия и остальная Европа. Ожидается, что Германия будет доминировать на рынке из-за растущих инициатив участников рынка и возросшего использования современных технологических инструментов.
Раздел отчета, посвященный странам, также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка внутри страны, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демография страны, эпидемиология заболеваний и импортно-экспортные пошлины, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность европейских брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, а также влияние на каналы продаж.
Конкурентная среда и анализ доли рынка лечения заболеваний опорно-двигательного аппарата (MSK) в Европе
Конкурентная среда европейского рынка лечения заболеваний опорно-двигательного аппарата (MSK) содержит сведения о конкуренте. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, присутствии в Европе, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта и доминировании в применении. Приведенные выше данные относятся только к фокусу компаний на рынке.
Некоторые из основных игроков, работающих на европейском рынке лечения заболеваний опорно-двигательного аппарата (MSK), включают RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH и Limber Health, Inc. и другие.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE SEGMENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 THE CATEGORY VS TIME GRID
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCE
4.3 KEY STRATEGIC INITIATIVES
4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
4.4.1 DIGITAL REHABILITATION
4.4.2 DIGITAL PHYSIOTHERAPY
5 EPIDEMOLOGY
5.1 US
5.2 CANADA
5.3 MEXICO
5.4 GERMANY
5.5 FRANCE
5.6 U.K.
5.7 ITALY
5.8 SPAIN
5.9 RUSSIA
5.1 TURKEY
5.11 BELGIUM
5.12 DENMARK
5.13 NETHERLANDS
5.14 SWITZERLAND
5.15 SWEDEN
5.16 POLAND
5.17 NORWAY
5.18 FINLAND
5.19 CHINA
5.2 JAPAN
5.21 SOUTH KOREA
5.22 INDIA
5.23 AUSTRALIA
5.24 NEW ZEALAND
5.25 SINGAPORE
5.26 THAILAND
5.27 MALAYSIA
5.28 VIETNAM
5.29 TAIWAN
5.3 INDONESIA
5.31 PHILIPPINES
5.32 BRAZIL
5.33 ARGENTINA
5.34 SOUTH AFRICA
5.35 SAUDI ARABIA
5.36 BAHRAIN
5.37 U.A.E
5.38 KUWAIT
5.39 OMAN
5.4 QATAR
5.41 EGYPT
5.42 ISRAEL
6 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS)
7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS)
7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA)
7.1.4 INCREASING CASES OF BONE FRACTURES
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES
7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.4 CHALLENGES
7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES
7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
8 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIGITAL BIOFEEDBACK SYSTEM
8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
8.3.1 IOS-SYSTEMS
8.3.2 ANDROID-SYSTEMS
8.3.3 OTHER SYSTEMS
8.4 SOLUTIONS
8.4.1 DIRECT SUPPORT
8.4.1.1 MULTIMODAL PAIN THERAPY
8.4.1.2 ONSITE PERSONALIZED THERAPY
8.4.1.3 SOLUTIONS TO REDUCE INJURIES
8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT
8.4.1.5 EARLY PREVENTION AND INTERVENTION
8.4.1.6 PREVENTION, RECOVERY AND EDUCATION
8.4.1.7 PERSONALIZED PAIN RECOVERY
8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY
8.4.1.9 TRAINING OF EDUCATION SKILLS
8.4.1.10 SELF-TRACKING OF PAIN EPISODES
8.4.1.11 RELAXATION TECHNIQUES
8.4.1.12 POST-OPERATIVE PAIN TRACKING
8.4.1.12.1 REAL-TIME MONITORING
8.4.1.12.2 SYMPTOM MANAGEMENT
8.4.1.13 OTHERS
8.4.2 PROGRESS TRACKING
8.4.3 OTHERS
8.5 OTHERS
9 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 PRECISION MOTION TECHNOLOGY
9.3 COMPUTER MOTION TECHNOLOGY
9.4 OTHER TECHNOLOGIES
10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE
10.1 OVERVIEW
10.2 PHONE
10.2.1 DIGITAL BIOFEEDBACK SYSTEM
10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.2.3 THERAPIES
10.2.4 OTHERS
10.3 TABLET
10.3.1 DIGITAL BIOFEEDBACK SYSTEM
10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.3.3 THERAPIES
10.3.4 OTHERS
10.4 COMPUTER
10.4.1 DIGITAL BIOFEEDBACK SYSTEM
10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.4.3 THERAPIES
10.4.4 OTHERS
10.5 OTHERS
11 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY
11.1 OVERVIEW
11.2 VIRTUAL THERAPY
11.2.1 INTERNET BASED
11.2.2 TELEPHONE BASED
11.2.3 MOBILE PHONE APPLICATION
11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
11.2.5 INTERACTIVE VOICE RESPONSE
11.2.6 VIDEO TELECONFERENCING
11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT
11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT
11.2.9 INTERNET BASED WITH VIDEO CONFERENCING
11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED
11.2.11 OTHERS
11.3 IN-PERSON THERAPY
11.4 CUSTOMIZED/ PERSONALIZED THERAPY
11.5 OTHERS
12 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 PRE-SURGERY APPLICATION
12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.2.5 MINIMALLY INVASIVE SPINE SURGERY
12.2.6 MOTION PRESERVING SPINE SURGERY
12.2.7 POSTERIOR CERVICAL FUSION SURGERY
12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.9 SACROILIAC JOINT FUSION SURGERY
12.2.10 SCOLIOSIS CORRECTION SURGERY
12.2.11 VERTEBRAL AUGMENTATION SURGERY
12.2.12 FRACTURE FIXATION SURGERY
12.2.13 HIP SURGERY
12.2.13.1 TOTAL HIP REPLACEMENT
12.2.13.2 PARTIAL HIP REPLACEMENT
12.2.13.3 HIP RESURFACING
12.2.13.4 OTHERS
12.2.14 KNEE SURGERY
12.2.14.1 TOTAL KNEE REPLACEMENT
12.2.14.2 PARTIAL KNEE REPLACEMENT
12.2.14.3 MISS FUSION
12.2.14.4 OTHERS
12.3 POST-SURGERY APPLICATION
12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.3.5 MINIMALLY INVASIVE SPINE SURGERY
12.3.6 MOTION PRESERVING SPINE SURGERY
12.3.7 POSTERIOR CERVICAL FUSION SURGERY
12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.9 SACROILIAC JOINT FUSION SURGERY
12.3.10 SCOLIOSIS CORRECTION SURGERY
12.3.11 VERTEBRAL AUGMENTATION SURGERY
12.3.12 FRACTURE FIXATION SURGERY
12.3.13 HIP SURGERY
12.3.13.1 TOTAL HIP REPLACEMENT
12.3.13.2 PARTIAL HIP REPLACEMENT
12.3.13.3 HIP RESURFACING
12.3.13.4 OTHERS
12.3.14 KNEE SURGERY
12.3.14.1 TOTAL KNEE REPLACEMENT
12.3.14.2 PARTIAL KNEE REPLACEMENT
12.3.14.3 MISS FUSION
12.3.14.4 OTHERS
13 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION
13.1 OVERVIEW
13.2 PEDIATRICS
13.2.1 MALE
13.2.2 FEMALE
13.3 ADULTS
13.3.1 MALE
13.3.2 FEMALE
13.4 GERIATRIC
13.4.1 MALE
13.4.2 FEMALE
14 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS & CLINICS
14.2.1 MULTIPLE
14.2.2 PHYSICAL THERAPIST
14.2.3 NURSE
14.2.4 HEALTH COACH
14.2.5 OTHERS
14.3 NURSING HOMES
14.3.1 MULTIPLE
14.3.2 PHYSICAL THERAPIST
14.3.3 NURSE
14.3.4 HEALTH COACH
14.3.5 OTHERS
14.4 HEALTH CENTERS
14.4.1 MULTIPLE
14.4.2 PHYSICAL THERAPIST
14.4.3 NURSE
14.4.4 HEALTH COACH
14.4.5 OTHERS
14.5 REHABILITATION CENTERS
14.5.1 MULTIPLE
14.5.2 PHYSICAL THERAPIST
14.5.3 NURSE
14.5.4 HEALTH COACH
14.5.5 OTHERS
14.6 VIRTUAL/HOME HEALTH CARE SETTINGS
14.6.1 MULTIPLE
14.6.2 PHYSICAL THERAPIST
14.6.3 NURSE
14.6.4 HEALTH COACH
14.6.5 OTHERS
14.7 OTHERS
15 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 FRANCE
15.1.3 U.K.
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 RUSSIA
15.1.7 TURKEY
15.1.8 BELGIUM
15.1.9 DENMARK
15.1.10 NETHERLANDS
15.1.11 SWITZERLAND
15.1.12 SWEDEN
15.1.13 POLAND
15.1.14 NORWAY
15.1.15 FINLAND
15.1.16 REST OF EUROPE
16 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 HINGE HEALTH, INC
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 SWORD HEALTH, INC
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.3 OMADA HEALTHA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 COMPANY SHARE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 KAIA HEALTH
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 WELLNESS COACHES USA, LLC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 AIRROSTI REHAB CENTER, LLC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DARIOHEALTH CORP.(2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 INCLUDEHEALTH (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 IMC (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 KIIO
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 LIMBER HEALTH, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 MOVEMENT RX (2021)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 PHZIO (2021)
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 RECOVERYONE
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 SPARTA SCIENCE
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 SPRITE HEALTH
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 SIMPLETHERAPY, INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Список таблиц
TABLE 1 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DIGITAL BIOFEEDBACK SYSTEM IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 8 EUROPE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 11 EUROPE PRECISION MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE COMPUTER MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE OTHER TECHNOLOGIES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 17 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 23 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 25 EUROPE IN-PERSON THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE CUSTOMIZED/ PERSONALIZED THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE GERIATRIC IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 45 EUROPE HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 49 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 53 EUROPE VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 EUROPE VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE MUSCULOSKELETAL DISEASE MANAGEMENT MARKET, BY COUNTRY, 2022-2030(USD MILLION)
TABLE 57 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 58 EUROPE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 59 EUROPE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 60 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 62 EUROPE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 63 EUROPE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 65 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 70 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 71 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 72 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 73 EUROPE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 74 EUROPE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 EUROPE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 EUROPE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 79 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 80 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 81 EUROPE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 82 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 83 EUROPE HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 84 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 86 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 87 EUROPE VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 88 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 90 GERMANY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 91 GERMANY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 92 GERMANY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 GERMANY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 94 GERMANY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 97 GERMANY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 98 GERMANY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 101 GERMANY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 102 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 GERMANY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 GERMANY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 GERMANY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 GERMANY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 GERMANY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 GERMANY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 110 GERMANY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 111 GERMANY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 112 GERMANY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 113 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 GERMANY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 116 GERMANY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 117 GERMANY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 118 GERMANY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 119 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 FRANCE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 121 FRANCE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 122 FRANCE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 FRANCE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 124 FRANCE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 125 FRANCE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 126 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 127 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 132 FRANCE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 133 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 134 FRANCE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 135 FRANCE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 FRANCE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 FRANCE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 FRANCE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 FRANCE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 141 FRANCE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 142 FRANCE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 143 FRANCE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 144 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 145 FRANCE HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 146 FRANCE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 147 FRANCE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 148 FRANCE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 149 FRANCE VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 150 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 U.K. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 152 U.K. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 153 U.K. MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 U.K. SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 U.K. DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 156 U.K. POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 158 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.K. PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.K. TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.K. COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 163 U.K. VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 164 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 U.K. PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.K. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.K. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 168 U.K. POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 U.K. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 170 U.K. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 172 U.K. PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 173 U.K. ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 174 U.K. GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 175 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 176 U.K. HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 177 U.K. NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 178 U.K. HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 181 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 ITALY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 183 ITALY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 184 ITALY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 185 ITALY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 ITALY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 187 ITALY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 189 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 194 ITALY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 195 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 ITALY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 197 ITALY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 198 ITALY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 199 ITALY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 200 ITALY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 201 ITALY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 202 ITALY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 203 ITALY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 204 ITALY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 205 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 206 ITALY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 207 ITALY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 208 ITALY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 209 ITALY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 210 ITALY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 211 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 212 SPAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 213 SPAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 214 SPAIN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 215 SPAIN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 216 SPAIN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 217 SPAIN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 219 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 SPAIN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 SPAIN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 SPAIN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 223 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 224 SPAIN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 225 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 226 SPAIN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 227 SPAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 228 SPAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 229 SPAIN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 SPAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 SPAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 232 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 233 SPAIN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 234 SPAIN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 235 SPAIN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 236 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 237 SPAIN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 238 SPAIN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 239 SPAIN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 240 SPAIN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 242 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 RUSSIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 244 RUSSIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 245 RUSSIA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 257 RUSSIA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 274 TURKEY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 275 TURKEY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 276 TURKEY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 278 TURKEY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 279 TURKEY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 281 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 282 TURKEY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 283 TURKEY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 284 TURKEY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 285 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 286 TURKEY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 287 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 TURKEY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 TURKEY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 TURKEY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 291 TURKEY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 292 TURKEY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 293 TURKEY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 294 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 295 TURKEY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 296 TURKEY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 297 TURKEY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 298 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 299 TURKEY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 300 TURKEY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 301 TURKEY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 302 TURKEY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 303 TURKEY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 304 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 BELGIUM DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 306 BELGIUM DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 307 BELGIUM MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 314 BELGIUM TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 315 BELGIUM COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 316 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 317 BELGIUM VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 318 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 319 BELGIUM PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 320 BELGIUM HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 321 BELGIUM KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 322 BELGIUM POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 BELGIUM HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 324 BELGIUM KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 325 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 326 BELGIUM PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 327 BELGIUM ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 328 BELGIUM GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 329 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 330 BELGIUM HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 331 BELGIUM NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 332 BELGIUM HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 333 BELGIUM REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 334 BELGIUM VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 335 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 336 DENMARK DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 337 DENMARK DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 338 DENMARK MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 339 DENMARK SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 340 DENMARK DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 341 DENMARK POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 342 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 343 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 344 DENMARK PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 345 DENMARK TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 346 DENMARK COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 347 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 348 DENMARK VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 349 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 DENMARK PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 DENMARK HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 352 DENMARK KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 DENMARK POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 354 DENMARK HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 355 DENMARK KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 356 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 357 DENMARK PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 358 DENMARK ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 359 DENMARK GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 360 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 361 DENMARK HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 362 DENMARK NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 363 DENMARK HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 364 DENMARK REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 365 DENMARK VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 368 NETHERLANDS DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 369 NETHERLANDS MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 371 NETHERLANDS DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 372 NETHERLANDS POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 374 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 375 NETHERLANDS PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 378 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 379 NETHERLANDS VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 381 NETHERLANDS PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 NETHERLANDS HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 384 NETHERLANDS POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 385 NETHERLANDS HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 392 NETHERLANDS HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 393 NETHERLANDS NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 394 NETHERLANDS HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 395 NETHERLANDS REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 396 NETHERLANDS VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 397 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 399 SWITZERLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 400 SWITZERLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 406 SWITZERLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 407 SWITZERLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 409 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 410 SWITZERLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 417 SWITZERLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 418 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 419 SWITZERLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 420 SWITZERLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 421 SWITZERLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 422 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 423 SWITZERLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 424 SWITZERLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 425 SWITZERLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 426 SWITZERLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 427 SWITZERLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 430 SWEDEN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 431 SWEDEN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 435 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 436 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 438 SWEDEN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 439 SWEDEN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 450 SWEDEN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 451 SWEDEN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 452 SWEDEN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 453 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 454 SWEDEN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 455 SWEDEN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 456 SWEDEN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 457 SWEDEN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 458 SWEDEN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 459 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 460 POLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 461 POLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 462 POLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 463 POLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 POLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 465 POLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 466 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 467 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 468 POLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 469 POLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 470 POLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 471 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 472 POLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 473 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 474 POLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 POLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 476 POLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 477 POLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 478 POLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 479 POLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 480 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 481 POLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 482 POLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 483 POLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 484 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 485 POLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 486 POLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 487 POLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 488 POLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 489 POLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 490 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 491 NORWAY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 492 NORWAY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 493 NORWAY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 494 NORWAY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 495 NORWAY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 496 NORWAY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 497 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 498 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 499 NORWAY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 500 NORWAY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 501 NORWAY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 502 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 503 NORWAY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 504 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 505 NORWAY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 506 NORWAY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 507 NORWAY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 508 NORWAY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 509 NORWAY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 510 NORWAY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 511 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 512 NORWAY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 513 NORWAY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 514 NORWAY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 515 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 516 NORWAY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 517 NORWAY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 518 NORWAY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 519 NORWAY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 520 NORWAY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 521 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 522 FINLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 523 FINLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 524 FINLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 525 FINLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 526 FINLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 527 FINLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 528 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 529 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 530 FINLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 531 FINLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 532 FINLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 533 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 534 FINLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 535 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 536 FINLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 537 FINLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 538 FINLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 539 FINLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 540 FINLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 541 FINLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 542 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 543 FINLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 544 FINLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 545 FINLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 546 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 547 FINLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 548 FINLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 549 FINLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 550 FINLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 551 FINLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 552 REST OF EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
Список рисунков
FIGURE 1 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE
FIGURE 3 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION
FIGURE 4 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT
FIGURE 5 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH
FIGURE 6 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH
FIGURE 7 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 11 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID
FIGURE 12 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION
FIGURE 13 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030
FIGURE 15 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY
FIGURE 16 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS
FIGURE 17 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS
FIGURE 18 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS
FIGURE 19 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS
FIGURE 20 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS
FIGURE 21 INCIDENSE OF FIBROMYALGIA
FIGURE 22 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME
FIGURE 23 PREVALENCE AND INCIDENCE OF BONE FRACTURES
FIGURE 24 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA
FIGURE 25 PREVALENCE AND INCIDENCE OF GOUT
FIGURE 26 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE TRANSPLANT DIAGNOSTICS MARKET
FIGURE 27 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022
FIGURE 28 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 29 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 30 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022
FIGURE 32 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022
FIGURE 36 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION)
FIGURE 37 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030)
FIGURE 38 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE
FIGURE 39 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022
FIGURE 40 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION)
FIGURE 41 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030)
FIGURE 42 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 43 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022
FIGURE 44 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 45 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 46 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 47 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022
FIGURE 48 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION)
FIGURE 49 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030)
FIGURE 50 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE
FIGURE 51 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022
FIGURE 52 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 53 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 54 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 55 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022)
FIGURE 56 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022)
FIGURE 57 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 58 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 59 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030)
FIGURE 60 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
